HCW Biologics Inc.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel fusion immunotherapeutics to treat conditions driven by chronic inflammation. Its pipeline targets autoimmune and proinflammatory diseases, cancer, and senescence-associated dysplasia. The company designs its product candidates using two proprietary platforms, TOBI and TRBC. Its lead clinical candidate, HCW9302, is an injectable fusion protein complex being evaluated for alopecia areata. HCW Biologics also develops commercial-ready reagent molecules, including HCW9201 and HCW9206, which serve biopharmaceutical customers producing CAR-T and natural killer cell therapies for cancer and infectious diseases.

Operationally, the company conducts its early clinical trials across two active clinical trial sites located at The Ohio State University and the James A. Haley Veterans' Hospital. In addition, the firm partners with Beijing Trimmune Biotech Co., Ltd., which holds licensing rights to advance candidate therapies in China and retains worldwide rights for another program. The company's clinical activities and trials are based in the United States.

Summary of the business section of HCW Biologics's latest annual report, written by StockData.